Home Contact Us Tip Us: [email protected]
Hot Stories
Recent Stories
A Thorough Comparison of MK-677 With Ipamorelin
Posted by Thandiubani on Thu 15th Feb, 2024 - tori.ngIpamorelin (NNC 26- 0161) is a pentapeptide synthesized from the met-enkephalin analog growth hormone-releasing peptide-1 (GHRP-1).
Although Ipamorelin and MK-677 are structurally and methodically different, both have suggested the potential to increase growth hormone levels within the organism. This all-inclusive manual explores the most recent scientific data about the potential of Ipamorelin and MK-677 for many hypothesized properties.
Ipamorelin Peptide: What is it?
Ipamorelin (NNC 26- 0161) is a pentapeptide synthesized from the met-enkephalin analog growth hormone-releasing peptide-1 (GHRP-1). While natural enkephalins operate on opioid receptors, GHRPs stimulate ghrelin receptors, which are involved in the stimulation of appetite. Growth hormone (GH) is secreted more readily when certain pituitary gland receptors, called "growth hormone secretagogue receptors," are activated.
Therefore, growth hormone secretagogues (GHSs) are substances like Ipamorelin that may activate the pituitary gland's ghrelin receptors. GHS can stimulate the production of other pituitary hormones, including prolactin and ACTH. Nevertheless, studies suggest that Ipamorelin is very selective since it alone may stimulate the anterior pituitary to produce GH.
Ipamorelin, created and patented in 1994 by Novo Nordisk and Helsinn Therapeutics, was intended to improve peristalsis in the digestive tract by mimicking the action of ghrelin.
Furthermore, according to preclinical investigations, the peptide seemed to have properties connected to its potential to enhance both GH and its anabolic mediator, insulin-like growth factor-1 (IGF-1). The following are some of the alleged properties seen in animal models:
- Possibly increased hunger and weight gain
- Possibly increased muscle strength and size
- Possibly increased bone density
MK-677: What is it?
It has been hypothesized to function similarly to GHRP-6, a peptide-based GHS, and is structurally characterized as a spiroindoline and a spiropiperidine. Research suggests that along with GHRP-6 and Ipamorelin, MK-677 may activate the pituitary gland's ghrelin receptors, producing GH via crossing the blood-brain barrier.
Scientists speculate that in the 1990s, Merck & Co. created MK-677 to combat growth hormone deficiency (GHD). The compound is believed to be an active GHS.
Research has indicated that MK-677 may significantly elevate GH and IGF-1 levels while having a brief but noticeable impact on cortisol and prolactin. Exposure may have the following practical effects in animal research models:
- Possibly enhanced muscular mass without corresponding increases in body fat
- Possible decrease in cholesterol levels
- Possibly enhanced sleep
A Thorough Comparison of MK-677 with Ipamorelin
Investigations purport that MK-677 and Ipamorelin may substantially raise GH and IGF-1 levels.
- Findings imply that within 40 minutes of being presented, Ipamorelin may cause a substantial increase in GH levels.
- Scientists speculate that although Ipamorelin has a half-life of less than two hours, the effects of its presentation to increase GH may last for two or three hours.
- According to the study's authors, GH seems to rise to around 26.6ng/ml (80mIU/l), which may be achieved with Ipamorelin.
- Additionally, Ipamorelin's presentation was associated with a 54% rise in IGF-I in animal studies. Contrarily, research indicates that MK-677 might have a much longer half-life of 4-6 hours.
MK-677 Peptide Properties
Research on the potential of MK 677 has linked its capacity to possibly elevate GH levels to an increase in muscle mass and other positive outcomes. We summarize some of the most important results of this GHS below:
- Possible gains in muscle and lean body mass: Compared to a placebo, obese animal models who were given MK-677 daily for eight weeks appeared to have gained lean body mass, with no variation in fat mass. Other investigations suggest that low-calorie intake may significantly reduce nitrogen losses.
- The longest published MK-677 study, which lasted 2 years, indicated that GHS daily may decrease LDL cholesterol levels, which are detrimental to the heart. After 12 months of presentation with MK-677, LDL levels appeared to have dropped by 0.14 mmol/l compared to a 0.12 mmol/l rise with placebo.
Ipamorelin Peptide Properties
Ipamorelin's potential for lean body mass, hunger, weight, and bone density has been the subject of much preclinical research. The following are the most important hypothesized results as concluded from animal test subjects:
- Studies suggest that Ipamorelin may potentially increase lean and fat mass, which might lead to a rise in weight and muscle. One study using healthy mice indicated a 16.9% increase in weight within two weeks of presentation. One possible explanation for this weight gain is that ghrelin receptor activation may increase hunger levels.
- Possibly preserving muscular strength: Ipamorelin was speculated to reduce muscle strength loss in mice, which may happen in corticosteroid-induced catabolic circumstances. Investigations purported that the peptide may potentially prevent muscular atrophy under certain circumstances.
- The research above asserted that Ipamorelin presentation may enhance bone mineralization in mice when given corticosteroids and Ipamorelin, compared to the control group that received just corticosteroids. Rat studies on females have implied that Ipamorelin may increase bone mineral content, leading to stronger and denser bones.
Visit Core Peptides for more educational articles and high-quality research compounds for investigation purposes only. Please note that none of the substances mentioned in this article have been approved for human consumption and should not be used by unlicensed individuals.
References
[i] Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
[ii] Johansen, N. L., Lau, J., Madsen, K., Lundt, B. F., Hansen, B. S., & Peschke, B. (1998). US Patent No. 5,767,085. Washington, DC: US Patent and Trademark Office.
[iii] Beck, D. E., Sweeney, W. B., McCarter, M. D., & Ipamorelin 201 Study Group (2014). Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease, 29(12), 1527–1534. https://doi.org/10.1007/s00384-014- 2030-8
[iv] National Library of Medicine (US). (January 20, 2011 – April 13, 2017). Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function. Identifier NCT01280344. https://www.clinicaltrials.gov/study/NCT01280344
[v] Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149–S159. https://doi.org/10.21037/tau.2019.11.30
[vi] Lee, J., Kwon, A., Chae, H. W., Lee, W. J., Kim, T. H., & Kim, H. S. (2018). Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Yonsei medical journal, 59(10), 1174–1180. https://doi.org/10.3349/ymj.2018.59.10.1174
[vii] Sigalos, J. T., & Pastuszak, A. W. (2018). The Safety and Efficacy of Growth Hormone Secretagogues. Sexual medicine reviews, 6(1), 45–53. https://doi.org/10.1016/j.sxmr.2017.02.004
[viii] Liu, H., Sun, D., Myasnikov, A., Damian, M., Baneres, J. L., Sun, J., & Zhang, C. (2021). Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren. Nature communications, 12(1), 6410. https://doi.org/10.1038/s41467-021-26735-5
[ix] Gobburu, J. V., Agersø, H., Jusko, W. J., & Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical research, 16(9), 1412–1416. https://doi.org/10.1023/a:1018955126402
[x] Andersen, N. B., Malmlöf, K., Johansen, P. B., Andreassen, T. T., Ørtoft, G., & Oxlund, H. (2001). The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 11(5), 266–272. https://doi.org/10.1054/ghir.2001.0239
Top Stories
Popular Stories
Stories from this Category
Recent Stories
